342 related articles for article (PubMed ID: 36250571)
1. Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study.
Wan EYF; Mok AHY; Yan VKC; Chan CIY; Wang B; Lai FTT; Chui CSL; Li X; Wong CKH; Lau CS; Wong ICK; Chan EWY
J Travel Med; 2022 Dec; 29(8):. PubMed ID: 36250571
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
3. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
Huang C; Wei Y; Yan VKC; Ye X; Kang W; Yiu HHE; Shami JJP; Cowling BJ; Tse ML; Castle DJ; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Hayes JF; Chang WC; Chung AKK; Lau CS; Wong ICK; Chan EW
Lancet Psychiatry; 2023 Jun; 10(6):403-413. PubMed ID: 37141907
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case-control study.
Yan VKC; Wan EYF; Ye X; Mok AHY; Lai FTT; Chui CSL; Li X; Wong CKH; Li PH; Ma T; Qin S; Wong VKC; Tsang TC; Tsui SH; Chui WCM; Cowling BJ; Leung GM; Lau CS; Wong ICK; Chan EWY
Emerg Microbes Infect; 2022 Dec; 11(1):2304-2314. PubMed ID: 35980089
[TBL] [Abstract][Full Text] [Related]
5. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
6. Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case-control study.
Yan VKC; Wan EYF; Ye X; Mok AHY; Lai FTT; Chui CSL; Li X; Wong CKH; Li PH; Ma T; Qin S; Lau CS; Wong ICK; Chan EWY
Emerg Microbes Infect; 2023 Dec; 12(1):2209201. PubMed ID: 37132361
[TBL] [Abstract][Full Text] [Related]
7. Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.
Leung NHL; Cheng SMS; Cohen CA; Martín-Sánchez M; Au NYM; Luk LLH; Tsang LCH; Kwan KKH; Chaothai S; Fung LWC; Cheung AWL; Chan KCK; Li JKC; Ng YY; Kaewpreedee P; Jia JZ; Ip DKM; Poon LLM; Leung GM; Peiris JSM; Valkenburg SA; Cowling BJ
Lancet Microbe; 2023 Sep; 4(9):e670-e682. PubMed ID: 37549680
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study.
Yan VKC; Cheng FWT; Chui CSL; Lai FTT; Wong CKH; Li X; Wan EYF; Wong JSC; Chan EWY; Wong ICK; Kwan MYW; Ip P
Emerg Microbes Infect; 2023 Dec; 12(1):2185455. PubMed ID: 36852582
[TBL] [Abstract][Full Text] [Related]
9. Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron.
Wei Y; Jia KM; Zhao S; Hung CT; Mok CKP; Poon PKM; Man Leung EY; Wang MH; Yam CHK; Chow TY; Guo Z; Yeoh EK; Chong KC
JAMA Netw Open; 2023 Feb; 6(2):e2254777. PubMed ID: 36735253
[TBL] [Abstract][Full Text] [Related]
10. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.
McMenamin ME; Nealon J; Lin Y; Wong JY; Cheung JK; Lau EHY; Wu P; Leung GM; Cowling BJ
Lancet Infect Dis; 2022 Oct; 22(10):1435-1443. PubMed ID: 35850128
[TBL] [Abstract][Full Text] [Related]
11. Vaccine Effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 in CKD.
Cheng FWT; Yan VKC; Wan EYF; Chui CSL; Lai FTT; Wong CKH; Li X; Chan CIY; Wang B; Tang SCW; Wong ICK; Chan EWY
Clin J Am Soc Nephrol; 2024 Apr; 19(4):418-428. PubMed ID: 38147590
[TBL] [Abstract][Full Text] [Related]
12. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
13. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
[TBL] [Abstract][Full Text] [Related]
14. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
15. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
16. Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data.
Kumwichar P; Poonsiri C; Botwright S; Sirichumroonwit N; Loharjun B; Thawillarp S; Cheewaruangroj N; Chokchaisiripakdee A; Teerawattananon Y; Chongsuvivatwong V
JMIR Public Health Surveill; 2024 Mar; 10():e48255. PubMed ID: 38441923
[TBL] [Abstract][Full Text] [Related]
17. Homologous and Heterologous Covid-19 Booster Vaccinations Against SARS-CoV-2 Infection in the Elderly.
Acer Ö; Genç Bahçe Y; Özüdoğru O
Curr Microbiol; 2024 May; 81(7):171. PubMed ID: 38739274
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months.
Low EV; Tok PSK; Husin M; Suah JL; Tng BH; Thevananthan T; Appannan MR; Yahaya H; Mohd Zin S; Muhamad Zin F; Sivasampu S; Peariasamy KM
JAMA Netw Open; 2022 Aug; 5(8):e2226046. PubMed ID: 35947381
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of BNT162b2 and Sinovac vaccines against the transmission of SARS-CoV-2 during Omicron-predominance in Hong Kong: A retrospective cohort study of COVID-19 cases.
Zhao S; Guo Z; Sun S; Hung CT; Leung EYM; Wei Y; Wang H; Li K; Yam CHK; Chow TY; Gao J; Jia KM; Chong KC; Yeoh EK
J Clin Virol; 2023 Sep; 166():105547. PubMed ID: 37453162
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during Omicron BA.2 wave in Hong Kong.
Leung D; Rosa Duque JS; Yip KM; So HK; Wong WHS; Lau YL
Commun Med (Lond); 2023 Jan; 3(1):3. PubMed ID: 36604522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
